Luminex eyes $64.5m new capital
This article was originally published in Clinica
Austin, Texas-based diagnostics company Luminex is looking to bag $64.5m in net proceeds from a public offering of 3.5 million new shares, priced at $19.91 per unit. The company, which developed the xMAP open-architecture, multi-analyte technology platform, intends to use the capital for general corporate purposes, which include R&D and potential acquisitions. The offering is expected to close June 30.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.